Capromorelin is an orally active ghrelin receptor agonist primarily utilized in veterinary medicine as an appetite stimulant, though it is investigated in humans for cachexia and sarcopenia. Users typically run doses ranging from 1 mg to 12 mg daily, with 12 mg being the most common amount, though specific timing and cycling schedules remain largely undefined in community reports. The primary tradeoff for those exploring this substance is that the human evidence base is significantly thinner than the current discourse suggests, as most exploratory indications lack published results and all human use remains strictly off-label or compounded.
Data last updated
Measured on 4 of 6 axes
Evidence shape
Capromorelin possesses a low tier of clinical evidence, limited to three published human studies focused on diagnostic, mechanistic, and treatment-based applications. The research landscape remains thin, consisting entirely of exploratory data without the support of registered, completed clinical trials to validate its efficacy or safety profile. Because the existing literature relies on single-trial observations and preclinical research, the current evidence base lacks the breadth and scale required to establish standardized therapeutic outcomes.
Efficacy signal
Completed studies are present, but primary-endpoint pass/fail classification is not yet clean enough to score. These are the currently projected indication-level signals.
Treatment studies
1 study
Diagnostic & mechanistic studies
2 studies
No completed study rows are available for endpoint scoring yet.
Human evidence
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Grouped from 2 published human studies — weighted by study count, not incidence (the papers report no rates).
Anecdotal side effects
No live vendor pricing captured for this peptide yet.
How Capromorelin is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
In the single reported research trial, participants were given Capromorelin orally at a fixed dose of 10 mg taken once each night.
No structured protocol details captured for this tier yet.
The three community reports cover a wide range: two cite 12 mg orally, while one reports 1 mg. No frequency or cycling data was provided in any of the reports, so cadence and duration remain unknown from this sample.